Trial Profile
A study to evaluate safety and efficacy of deferasirox in patients with β-thalassemia major
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Nov 2015
Price :
$35
*
At a glance
- Drugs Deferasirox (Primary)
- Indications Beta-thalassaemia
- Focus Therapeutic Use
- 27 Nov 2015 New trial record
- 01 Feb 2014 Primary endpoint (improvement in the severity of liver and cardiac iron overload) has been met, according to results published in the Pediatric Hematology and Oncology.